In reviewing the content of the claims in this batch of warning letters, most of the concerning language on online websites advertising these products that was flagged by the FDA is unsurprising, including: Named the brand product as a comparative reference or therapeutic equivalent Stated the compounded product was a generic of the brand product Included efficacy claims for the compounded product Used the words FDA-approved in the advertising copy But some of the language that was flagged by the FDA was less direct, with the FDAs expressed concern being that the advertising may have given the impression of FDA approval
1 Two other glucagon-like peptide-1 receptor agonist (GLP-1) medications, tirzepatide and liraglutide, have also been approved for weight loss by the FDA
Growth hormone secretagogues A growth hormone secretagogue, such as tesamorelin, is a compound that causes the body to increase its growth hormone levels
However, the majority of EECs express several hormones that overlap between different enteroendocrine cells
The gallbladder-related side effects associated with semaglutide generally manifest as cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder)
Semaglutide 3mg tablet is a part of the GLP-1 (glucagon-like peptide) group of diabetes medications
